This inventor holds 22 USPTO granted patents and 13 EPO patents, primarily in HIV And Hepatitis C Treatment. Top assignees: Bristol-Myers Squibb Compnay, Viiv Healthcare UK (No.5) Limited, Bristol Meyers Squibb Company. Active years: 1995-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Middletown, CT (US) (1995 - 2001)
- Meriden, CT (US) (2005 - 2007)
- Wallingford, CT (US) (2010 - 2018)
Company Filing History:
19 out of 3,737 
2 out of 45 
1 out of 41 Years Active: 1995-2018
Areas of Expertise:
Title: The Innovations of Stanley V D'Andrea
Introduction
Stanley V D'Andrea, based in Middletown, Connecticut, is a prominent figure in the field of pharmaceutical inventions. With a remarkable portfolio boasting 22 patents, his contributions particularly influence the landscape of HIV treatment through innovative compounds.
Latest Patents
Among his latest patents, D'Andrea has developed "Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication." This disclosure relates to compounds that are vital in formulating compositions and methods aimed at treating HIV infection. The innovative compounds presented provide novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methodologies for their application in the treatment of HIV infection.
Additionally, he has filed another patent titled “Inhibitors of Human Immunodeficiency Virus Replication,” which similarly focuses on compounds meant to combat HIV. This underscores his commitment to advancing scientific understanding and treatment methodologies for critical health issues.
Career Highlights
Throughout his illustrious career, Stanley V D'Andrea has worked with respected organizations such as Bristol-Myers Squibb Company and ViiV Healthcare UK (No. 5) Limited. His tenure at these companies has allowed him to expand his expertise and contribute significantly to pharmaceutical innovations.
Collaborations
D'Andrea has collaborated with notable colleagues including Zhizhen Barbara Zheng and Paul Michael Scola. Their combined expertise highlights the collaborative nature of scientific research and development, facilitating advancements in combating viral infections such as HIV.
Conclusion
Stanley V D'Andrea’s innovative work and extensive patents reflect his dedication to pharmaceutical research and development, especially concerning HIV infection treatment. His collaborations and career pathways set a significant precedent in the field, encouraging ongoing innovation and discovery.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile